Leading the Way in Psychedelic-based Mental Health Treatments
At Optimi Health, we are leading the way in GMP-certified psychedelic therapies, delivering innovative treatments that advance mental health care worldwide. With a focus on quality, compliance, and patient outcomes, we’re shaping a brighter future for mental wellness. Explore our journey and discover the impact of transformative science.
At Optimi Health, we are leading the way in GMP-certified psychedelic therapies, delivering innovative treatments that advance mental health care worldwide. With a focus on quality, compliance, and patient outcomes, we’re shaping a brighter future for mental wellness. Explore our journey and discover the impact of transformative science.
Drug Establishment License & GMP Manufacturing
Drug Establishment License & GMP Manufacturing
Global Export for MDMA & Psilocybin Capsules
Global Export for MDMA & Psilocybin Capsules
Backed by +CA$30M in Strategic Funding
Backed by +CA$30M in Strategic Funding
Pioneering Accessible Psychedelic Therapies Worldwide
Optimi Health Corp. is a Canadian drug manufacturer licensed by Health Canada to produce and supply psychedelic substances like MDMA, GMP-grade psilocybin, and functional mushrooms for health and wellness markets.
The use of psychedelics as a groundbreaking treatment for depression and mental health disorders is growing globally. Optimi Health delivers cost-effective, GMP-certified MDMA and psilocybin to regulated markets worldwide under Health Canada’s Drug Establishment License.
Opportunities with Optimi Health
With regulatory approvals, GMP-certified production, and growing demand, Optimi Health offers unique opportunities for investors, partners, and researchers in the expanding psychedelic industry.
Opportunities with Optimi Health
With regulatory approvals, GMP-certified production, and growing demand, Optimi Health offers unique opportunities for investors, partners, and researchers in the expanding psychedelic industry.
Opportunities with Optimi Health
With regulatory approvals, GMP-certified production, and growing demand, Optimi Health offers unique opportunities for investors, partners, and researchers in the expanding psychedelic industry.
MDMA: Precision-Engineered for Therapeutic Use
Optimi’s GMP-certified MDMA capsules are designed for clinical trials and therapeutic applications under strict regulatory standards. With exceptional purity, validated manufacturing processes, and proven stability, Optimi ensures high-quality, scalable production to meet global demand.
Application & Validation
Optimi’s MDMA is manufactured for use in Australia’s Authorized Prescribers Scheme and global clinical trials. Its production meets rigorous GMP standards, with validated processes ensuring consistent quality, sanitation, and compliance. Analytical testing confirms exceptional purity (>99%) and product reliability.
Application & Validation
Optimi’s MDMA is manufactured for use in Australia’s Authorized Prescribers Scheme and global clinical trials. Its production meets rigorous GMP standards, with validated processes ensuring consistent quality, sanitation, and compliance. Analytical testing confirms exceptional purity (>99%) and product reliability.
Application & Validation
Optimi’s MDMA is manufactured for use in Australia’s Authorized Prescribers Scheme and global clinical trials. Its production meets rigorous GMP standards, with validated processes ensuring consistent quality, sanitation, and compliance. Analytical testing confirms exceptional purity (>99%) and product reliability.
Availability & Quality
MDMA capsules are available in 40mg and 60mg dosages for oral administration. They are produced under strict GMP guidelines, with third-party testing verifying identity, purity, and compliance with quality standards.
Availability & Quality
MDMA capsules are available in 40mg and 60mg dosages for oral administration. They are produced under strict GMP guidelines, with third-party testing verifying identity, purity, and compliance with quality standards.
Availability & Quality
MDMA capsules are available in 40mg and 60mg dosages for oral administration. They are produced under strict GMP guidelines, with third-party testing verifying identity, purity, and compliance with quality standards.
Stability & Scalability
MDMA capsules are stable for extended periods under real-time and accelerated storage conditions. Optimi’s in-house capabilities enable efficient large-scale production, ensuring readiness to meet global market demands.
Stability & Scalability
MDMA capsules are stable for extended periods under real-time and accelerated storage conditions. Optimi’s in-house capabilities enable efficient large-scale production, ensuring readiness to meet global market demands.
Stability & Scalability
MDMA capsules are stable for extended periods under real-time and accelerated storage conditions. Optimi’s in-house capabilities enable efficient large-scale production, ensuring readiness to meet global market demands.
Psilocybin Extract: Advancing Mental Health Solutions
Optimi’s natural psilocybin extract is tailored for treating mental health conditions like TRD. Produced under GMP compliance and validated for safety and efficacy, the extract offers exceptional quality, stability, and scalability to support global therapeutic and research initiatives.
Application & Validation
Optimi’s psilocybin extract is designed for treatment-resistant depression (TRD) within Australia’s Authorized Prescribers Scheme and global clinical trials. Manufactured under GMP standards, its development follows International Council for Harmonization (ICH) guidelines, ensuring safety and efficacy.
Application & Validation
Optimi’s psilocybin extract is designed for treatment-resistant depression (TRD) within Australia’s Authorized Prescribers Scheme and global clinical trials. Manufactured under GMP standards, its development follows International Council for Harmonization (ICH) guidelines, ensuring safety and efficacy.
Application & Validation
Optimi’s psilocybin extract is designed for treatment-resistant depression (TRD) within Australia’s Authorized Prescribers Scheme and global clinical trials. Manufactured under GMP standards, its development follows International Council for Harmonization (ICH) guidelines, ensuring safety and efficacy.
Availability & Quality
Psilocybin is available in 5mg capsules for therapeutic use and 10mg R&D-grade capsules for clinical studies. Rigorous testing confirms compliance with quality specifications, including potency, water content, microbial limits, and heavy metal safety.
Availability & Quality
Psilocybin is available in 5mg capsules for therapeutic use and 10mg R&D-grade capsules for clinical studies. Rigorous testing confirms compliance with quality specifications, including potency, water content, microbial limits, and heavy metal safety.
Availability & Quality
Psilocybin is available in 5mg capsules for therapeutic use and 10mg R&D-grade capsules for clinical studies. Rigorous testing confirms compliance with quality specifications, including potency, water content, microbial limits, and heavy metal safety.
Stability & Scalability
Psilocybin maintains potency with no degradation during nine months of stability testing. With the world’s largest genetic bank and a storage capacity of 2,000kg, Optimi is prepared for scalable, high-volume production.
Stability & Scalability
Psilocybin maintains potency with no degradation during nine months of stability testing. With the world’s largest genetic bank and a storage capacity of 2,000kg, Optimi is prepared for scalable, high-volume production.
Stability & Scalability
Psilocybin maintains potency with no degradation during nine months of stability testing. With the world’s largest genetic bank and a storage capacity of 2,000kg, Optimi is prepared for scalable, high-volume production.
"Australian psychiatrists can now prescribe Optimi’s MDMA and Psilocybin capsules for therapeutic use in patients. To have both of these GMP drugs in market is a very humbling achievement"
"Australian psychiatrists can now prescribe Optimi’s MDMA and Psilocybin capsules for therapeutic use in patients. To have both of these GMP drugs in market is a very humbling achievement"
JJ Wilson
CO-FOUNDER & CHAIRMAN OPTIMI HEALTH
Latest News
Latest News
Subscribe to our Newsletter
Stay updated with the latest information and news.
Subscribe to our Newsletter
Stay updated with the latest information and news.
Subscribe to our Newsletter
Stay updated with the latest information and news.
Optimi Health is a Health Canada-licensed GMP pharmaceutical manufacturer specializing in MDMA and psilocybin. Committed to advancing mental health treatments, we deliver high-quality, cost-effective solutions for global markets.
Reach Us
Optimi Health is a Health Canada-licensed GMP pharmaceutical manufacturer specializing in MDMA and psilocybin. Committed to advancing mental health treatments, we deliver high-quality, cost-effective solutions for global markets.
Reach Us
Optimi Health is a Health Canada-licensed GMP pharmaceutical manufacturer specializing in MDMA and psilocybin. Committed to advancing mental health treatments, we deliver high-quality, cost-effective solutions for global markets.